Dec 18, 2006 | www.fda.gov
FDA and Genentech informed healthcare professionals of important emerging safety information about Rituxan. Two patients died after being treated with Rituxan for systemic lupus erythematosus (SLE). Rituxan is approved for the above indication and is prescribed off-label for other serious diseases and conditions such as SLE. The cause of death was a viral infection of the brain called progressive multifocal leukoencephalopathy (PML) that is caused by reactivated JC virus which is present in about 80 percent of adults. Physicians should maintain a high index of suspicion for the development of PML in patients under treatment with Rituxan.
Please note that you are not considered a client until you have signed a retainer agreement and your case has been accepted by us. Prior results do not guarantee or predict a similar outcome with respect to any future matter. | Attorney Advertising.